IL304971A - Humanized anti-S100A4 antibody, uses and methods - Google Patents

Humanized anti-S100A4 antibody, uses and methods

Info

Publication number
IL304971A
IL304971A IL304971A IL30497123A IL304971A IL 304971 A IL304971 A IL 304971A IL 304971 A IL304971 A IL 304971A IL 30497123 A IL30497123 A IL 30497123A IL 304971 A IL304971 A IL 304971A
Authority
IL
Israel
Prior art keywords
antibody
seq
cancer
amino acid
region
Prior art date
Application number
IL304971A
Other languages
English (en)
Hebrew (he)
Original Assignee
Arxx Therapeutics As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arxx Therapeutics As filed Critical Arxx Therapeutics As
Publication of IL304971A publication Critical patent/IL304971A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL304971A 2021-02-09 2022-02-09 Humanized anti-S100A4 antibody, uses and methods IL304971A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163147483P 2021-02-09 2021-02-09
PCT/EP2022/053095 WO2022171656A1 (en) 2021-02-09 2022-02-09 Anti-s100a4 humanized antibodies, uses and methods

Publications (1)

Publication Number Publication Date
IL304971A true IL304971A (en) 2023-10-01

Family

ID=80446273

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304971A IL304971A (en) 2021-02-09 2022-02-09 Humanized anti-S100A4 antibody, uses and methods

Country Status (8)

Country Link
US (2) US20240043521A1 (enExample)
EP (1) EP4291579A1 (enExample)
JP (2) JP7824969B2 (enExample)
CN (1) CN117480182A (enExample)
AU (1) AU2022219476A1 (enExample)
CA (1) CA3207703A1 (enExample)
IL (1) IL304971A (enExample)
WO (1) WO2022171656A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022003042A1 (en) * 2020-06-30 2022-01-06 Arxx Therapeutics As Anti-s100a4 antibodies for the treatment of systemic sclerosis
EP4433084A1 (en) * 2021-11-19 2024-09-25 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
CN115819577B (zh) * 2022-10-08 2026-06-12 河南赛诺特生物技术有限公司 一种抗s100a单克隆抗体及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103201290B (zh) * 2010-06-14 2016-09-28 莱克拉生物医学股份公司 S100a4抗体及其治疗用途
GB201219487D0 (en) * 2012-10-30 2012-12-12 Cancer Rec Tech Ltd Anti-S100A4 antibody molecules and their uses
EA201892716A1 (ru) * 2016-06-14 2019-05-31 Мерк Шарп И Доум Корп. Антитела к фактору свертывания xi
CN107375923A (zh) * 2017-07-06 2017-11-24 北京多赢时代转化医学研究院 抗s100a4抗体在抗cd137抗体介导抗肿瘤免疫损伤中的应用
CN109912717B (zh) * 2019-03-04 2020-05-26 北京天广实生物技术股份有限公司 结合cd40的抗体及其用途
WO2022003042A1 (en) * 2020-06-30 2022-01-06 Arxx Therapeutics As Anti-s100a4 antibodies for the treatment of systemic sclerosis

Also Published As

Publication number Publication date
US20250092125A1 (en) 2025-03-20
US20240043521A1 (en) 2024-02-08
JP2026094227A (ja) 2026-06-09
JP2024509701A (ja) 2024-03-05
WO2022171656A1 (en) 2022-08-18
US12304949B2 (en) 2025-05-20
CA3207703A1 (en) 2022-08-18
CN117480182A (zh) 2024-01-30
JP7824969B2 (ja) 2026-03-05
EP4291579A1 (en) 2023-12-20
AU2022219476A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
US12037392B2 (en) Treatment regimens using anti-NKG2A antibodies
US20240002515A1 (en) Methods and antibodies for modulation of immunoresponse
JP7730764B2 (ja) アンタゴニスト抗ｃｄ７抗体
US20220064312A1 (en) Novel Anti-CCR8 Antibody
KR102663440B1 (ko) 인간화된 항-ccr7 리셉터 항체
DK2403528T3 (en) ANTIBODIES AGAINST A proliferation-inducing ligand (April)
US12304949B2 (en) Anti-S100A4 humanized antibodies, uses and methods
JP2020072715A (ja) 抗ｃｘｃｒ３抗体
JP2020514363A (ja) 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５
JP2022514179A (ja) 新規アゴニスト抗ｔｎｆｒ２抗体分子
JP7843824B2 (ja) 抗体および使用方法
US20260116991A1 (en) Monoclonal antibody for specifically recognizing glypican-3, and application thereof
JP2022512905A (ja) 新規アンタゴニスト抗ｔｎｆｒ２抗体分子
CN114729053A (zh) 一种4-1bb结合蛋白及其应用
JP7430137B2 (ja) 抗体および使用方法
CN113307874B (zh) 一种抗lag3的抗体及其应用
WO2023125652A1 (zh) 抗cd40×cldn18.2双特异性抗体及其用途
CN116848144A (zh) 抗pd-l1抗体及其用途
KR20230015331A (ko) 항-cd47 항체 및 그의 용도
RU2782462C1 (ru) Новое антитело против ccr8
WO2022262749A1 (zh) 靶向pd1和/或ox40的特异性结合蛋白
CN114773485A (zh) 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
CN119661708A (zh) 靶向cd27的单克隆抗体及其用途
CN121949560A (zh) 一种结合pd-l1和vegf的双特异性抗体及其用途
HK40076446A (en) 4-1bb binding protein and application thereof